Lexaria Awarded Six Additional Patents
Rhea-AI Summary
Lexaria (Nasdaq:LEXX) announced six newly granted patents, bringing its total to 60 granted patents across major global markets as of January 22, 2026.
The six grants include: Australia (first patent) for Family #20 (sublingual nicotine); EU (first patent) for Family #21 (hypertension); two Australia and one EU patents for Family #24 (epilepsy); and one new US patent for Family #27 (diabetes), bringing that family to two US patents.
Shareholders are reminded to vote at the Annual Meeting on January 27, 2026 at 1:00 PM PT.
Positive
- Total patents increased to 60 granted worldwide
- Six new patents granted across US, Australia, and EU
- First EU patent in Family #21 (hypertension) — EU market strategic
- Family #24 (epilepsy) now has 6 US and 4 Australian patents
- Family #27 (diabetes) now has 2 US patents
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
LEXX gained 8.74% while peers were mixed: ASBP -4.98%, CING -7.21%, CRIS -8.95%, PMN +0.14%, NRXS +8.15%. Only one peer shows strong upside, supporting a stock-specific response to the patent and meeting news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | CEO annual letter | Positive | +3.2% | CEO outlined 2025 R&D progress, patent growth to 56 and $9.5M financing. |
| Dec 30 | Clinical data update | Positive | -2.9% | Released additional positive results from Phase 1b GLP‑1‑H24‑4 study. |
| Dec 23 | Primary endpoint hit | Positive | -8.0% | Announced Phase 1b GLP‑1‑H24‑4 met safety and tolerability primary endpoint. |
| Dec 16 | Offering closing | Negative | -5.6% | Closed $3.5M registered direct offering with accompanying warrants. |
| Dec 15 | Offering announced | Negative | -33.6% | Announced $3.5M registered direct offering priced at-the-market. |
Positive clinical or IP updates have sometimes seen negative reactions, while equity offerings have generally aligned with downside moves.
Over the past two months, Lexaria has reported multiple milestones: successful Phase 1b GLP‑1 study results, additional data from the GLP‑1‑H24‑4 trial, and an annual CEO letter highlighting 56 worldwide patents and $9.5M raised in 2025. It also completed and announced a registered direct offering of $3.5M, which coincided with sharp share-price declines. Today’s patent update, lifting the total to 60 granted patents, extends that IP expansion narrative ahead of the 2026 shareholder meeting.
Market Pulse Summary
This announcement expands Lexaria’s patent portfolio to 60 granted patents, including new protections in Australia, the European Union and the US for nicotine, hypertension, epilepsy and diabetes applications, while also reminding holders to vote at the January 27, 2026 annual meeting. In recent months, the company combined positive GLP‑1 trial readouts and IP growth with dilutive offerings. Investors may watch future financing actions, partnership progress and additional patent wins as key markers of execution.
Key Terms
sublingual delivery medical
hypertension medical
epilepsy medical
diabetes medical
GLP-1 medical
proxy statement regulatory
AI-generated analysis. Not financial advice.
Lexaria now has 60 patents granted around much of the world
Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting
KELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has reached yet another important milestone in its strategy of building a strong and diverse intellectual property portfolio: the Company now has a total of 60 valid patents granted around most of the major potential markets around the world.
Lexaria's previous update on patents was issued on October 9, 2025. Since then, we have diligently pursued legal recognition of our innovations leading to intellectual property and are delighted to have enjoyed considerable success through the receipt of 6 new granted patents.
In our patent Family #20, Compositions and Methods for Sublingual Delivery of Nicotine, where we have existing granted patents in the US, Canada, and Japan, we have received our first patent in Australia.
We have received our first European Union patent in patent Family #21, Compositions and Methods for Treating Hypertension, where we already have 3 US granted patents. Europe is considered the 2nd-largest hypertension market in the world (following the US) and thus receiving European patent recognition is an important milestone.
In our patent Family #24, Compositions and Methods for Treating Epilepsy, we have received 2 new Australian patents and 1 new European Union patent. Our intellectual property in this important Family is now quite robust with a total of 6 US patents; 4 Australian patents; and 1 European Union patent.
Finally, in our patent Family #27, Compositions and Methods for Treating Diabetes, we have received 1 new US patent. We now have 2 US patents in this Family which we consider to be quite important given our recent successes in the GLP-1 sector.
Lexaria's exceptional innovations are evidenced through its robust patent portfolio. Initial hypotheses are first evaluated through research of existing scientific papers; followed by the all-important animal and/or human testing to generate data that subsequently supports patent applications in the numerous international markets that we have pursued. Only after patents are granted are we most able to safely pursue commercial relationships to exploit our innovations.
2026 Annual Shareholder Meeting Voting Reminder
The Company would like to remind shareholders to *** VOTE YOUR SHARES *** in Lexaria's upcoming Annual Meeting which will be held on January 27, 2026, at 1:00 PM PT.
Stockholders holding common stock at the close of business on December 1, 2025 are entitled to vote at the meeting, even if they have subsequently sold their shares.
Lexaria is asking stockholders to follow their Board of Directors' recommendation to vote FOR all proposals. Regardless of how you vote, we strongly encourage you to vote your shares on each or on any of the proposals contained in the proxy statement - your opinions matter to us!
How to Access the Proxy Materials
The proxy statement and annual report to security holders are available online at: www.colonialstock.com/LEXX2026.
On the above website, you can vote by entering your control number; it's easy! The control number is located on your proxy materials. If you received an email notice, your control number is contained in the email. If you haven't received a control number, call your broker and ask for one.
Lexaria shareholders are encouraged to read the proxy statement and annual report filed in connection with the Meeting in detail and cast your votes prior to the proxy voting deadline (4:00 PM PT on January 26, 2026).
About Lexaria Bioscience Corp. & DehydraTECH
DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 60 patents granted and additional patents pending worldwide. For more information, please visit www.lexariabioscience.com.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
INVESTOR CONTACT:
George Jurcic - Head of Investor Relations
ir@lexariabioscience.com
Phone: 250-765-6424, ext 202
SOURCE: Lexaria Bioscience Corp.
View the original press release on ACCESS Newswire
FAQ
What patents did Lexaria (LEXX) announce on January 22, 2026?
Which Lexaria patent families received new grants in January 2026?
How does the new EU patent affect Lexaria's hypertension IP (LEXX)?
When is the Lexaria (LEXX) 2026 Annual Meeting and who can vote?
Where can Lexaria shareholders access proxy materials and vote for LEXX?
